Nothing Special   »   [go: up one dir, main page]

MX2020010075A - Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos. - Google Patents

Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos.

Info

Publication number
MX2020010075A
MX2020010075A MX2020010075A MX2020010075A MX2020010075A MX 2020010075 A MX2020010075 A MX 2020010075A MX 2020010075 A MX2020010075 A MX 2020010075A MX 2020010075 A MX2020010075 A MX 2020010075A MX 2020010075 A MX2020010075 A MX 2020010075A
Authority
MX
Mexico
Prior art keywords
lysin
polypeptide constructs
polynucleotides encoding
lysins
isolated polynucleotides
Prior art date
Application number
MX2020010075A
Other languages
English (en)
Inventor
Raymond Schuch
Original Assignee
Contrafect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contrafect Corp filed Critical Contrafect Corp
Publication of MX2020010075A publication Critical patent/MX2020010075A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente descripción se dirige a construcciones de lisina-polipéptidos AMP, polipéptidos de lisina aislados y composiciones farmacéuticas que comprenden los polipéptidos aislados y/o construcciones de lisina-polipéptidos AMP. También se proporcionan en este documento métodos para usar las construcciones de lisina-polipéptidos AMP, polipéptidos de lisina aislados y composiciones farmacéuticas, incluidos métodos para tratar una infección bacteriana de un órgano o tejido en el que está presente un tensioactivo pulmonar o infecciones bacterianas Gramnegativas que están asociadas con una biopelícula. Además, los polinucleótidos aislados que codifican para las construcciones de lisina polipéptido AMP y los polipéptidos de lisina aislados se describen en este documento.
MX2020010075A 2018-03-29 2019-03-29 Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos. MX2020010075A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862650235P 2018-03-29 2018-03-29
US201862721969P 2018-08-23 2018-08-23
US201862722793P 2018-08-24 2018-08-24
PCT/US2019/024912 WO2019191633A2 (en) 2018-03-29 2019-03-29 Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof

Publications (1)

Publication Number Publication Date
MX2020010075A true MX2020010075A (es) 2021-01-08

Family

ID=68060804

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010075A MX2020010075A (es) 2018-03-29 2019-03-29 Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos.

Country Status (11)

Country Link
US (2) US11773140B2 (es)
EP (1) EP3775192A4 (es)
JP (1) JP2021519083A (es)
KR (1) KR20200136980A (es)
CN (1) CN112368376A (es)
AU (1) AU2019245369A1 (es)
BR (1) BR112020019484A2 (es)
CA (1) CA3095484A1 (es)
IL (1) IL277119A (es)
MX (1) MX2020010075A (es)
WO (1) WO2019191633A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2767294T3 (es) * 2014-06-26 2020-06-17 Univ Rockefeller Lisinas de Acinetobacter
KR20200098615A (ko) 2017-12-12 2020-08-20 콘트라펙트 코포레이션 사람 혈청의 존재하에 슈도모나스 아에루기노사에 대해 살균 활성을 갖는 리신 및 이의 유도체
US10988520B2 (en) * 2018-03-29 2021-04-27 Contrafect Corporation Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
WO2019191598A1 (en) * 2018-03-29 2019-10-03 Contrafect Corporation Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria
MX2020010075A (es) 2018-03-29 2021-01-08 Contrafect Corp Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos.
WO2020206327A1 (en) * 2019-04-05 2020-10-08 Contrafect Corporation Lysins and derivatives thereof with bactericidal activity against pseudomonas aeruginosa, in the presence of human serum
US20220401514A1 (en) * 2019-07-05 2022-12-22 Contrafect Corporation Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative and acid-fast bacteria
EP4058468A4 (en) * 2019-11-14 2024-04-10 Contrafect Corporation POLYPEPTIDE CONSTRUCTIONS OF ANTIMICROBIAL PEPTIDE LYSINE (AMP), LYSINES, ISOLATED POLYNUCLEOTIDES ENCODING THEREFOR AND USES THEREOF
WO2021211303A1 (en) * 2020-04-14 2021-10-21 Contrafect Corporation Antiviral, bacteriophage-derived polypeptides and their use against viruses
US20210324359A1 (en) * 2020-04-17 2021-10-21 Contrafect Corporation Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in treating endocarditis
AU2022242830A1 (en) * 2021-03-26 2023-11-02 Contrafect Corporation Amurins lysins, and lysin-antimicrobial peptide (amp) constructs active against gram-negative bacteria
WO2022236088A1 (en) * 2021-05-06 2022-11-10 Bioharmony Therapeutics Inc. Lysin polypeptide compositions and methods of use
FR3149209A1 (fr) * 2023-06-02 2024-12-06 L'oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un alcool aromatique
FR3149202A1 (fr) * 2023-06-02 2024-12-06 L'oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et une huile.
FR3149203A1 (fr) * 2023-06-02 2024-12-06 L'oreal Composition anhydre comprenant une endolysine et de l’hydroxypropylmethylcellulose et/ou du pullulane
WO2024246325A1 (en) * 2023-06-02 2024-12-05 L'oreal Cosmetic composition comprising an endolysin derived from a staphylococcus aureus phage and an aromatic alcohol
WO2024256710A2 (en) 2023-06-15 2024-12-19 Aurobac Therapeutics Sas Engineered lysin polypeptide constructs active against gram-negative bacteria

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2007003991A0 (en) 2004-11-12 2007-06-30 Novozymes As Polypeptides having antimicrobial activity and polynucleotides encoding same
SG176783A1 (en) * 2009-06-16 2012-01-30 Univ Tokai Anti-gram-negative bacteria agent
EP3714895A3 (en) * 2009-06-26 2020-11-25 Lysando AG Antimicrobial agents
BRPI1015203B1 (pt) 2009-06-26 2021-06-01 Lysando Ag Proteína de fusão composta por uma endolisina e uma extensão de peptídeo anfifática, usos da mesma e composição farmacêutica que compreende a dita proteína
MX2012002216A (es) 2009-08-24 2012-04-10 Univ Leuven Kath Nueva endolisina obpgplys.
EP2468856A1 (en) * 2010-12-23 2012-06-27 Lysando Aktiengesellschaft Antimicrobial Agents
AU2012245391A1 (en) 2011-04-21 2013-11-21 The Rockefeller University Streptococcus bacteriophage lysins for treatment of gram positive bacteria in companion animals and livestock
US20140120074A1 (en) * 2011-04-27 2014-05-01 Lysando Ag Antimicrobial agents
US9518252B2 (en) 2011-05-26 2016-12-13 Dsm Ip Assets B.V. Listeria bacteriophage P825 and uses thereof
US8790639B2 (en) 2012-03-28 2014-07-29 The United States Of America, As Represented By The Secretary Of Agriculture Enhanced antimicrobial lytic activity of a chimeric Ply187 endolysin
KR101391332B1 (ko) 2012-05-18 2014-05-07 연세대학교 산학협력단 카바페넴 제제에 내성을 보이는 아시네토박터 속의 균을 용균하는 박테리오파아지
US9388400B2 (en) * 2012-06-29 2016-07-12 Lysando Ag Composition for use in mycobacteria diagnosis
CN102861324A (zh) 2012-10-17 2013-01-09 重庆市第三人民医院 治疗耐碳青霉烯类鲍曼不动杆菌感染的生物试剂
ES2767294T3 (es) 2014-06-26 2020-06-17 Univ Rockefeller Lisinas de Acinetobacter
JP7029805B2 (ja) * 2015-09-17 2022-03-04 コントラフェクト コーポレイション グラム陰性菌に対して活性を有する溶解素ポリペプチド
KR102000120B1 (ko) 2017-01-26 2019-07-15 주식회사 코미팜 이유 자돈의 대장균증을 예방하기 위한 재조합 p22 라이소자임 - pmap36 융합 단백질을 이용한 장내독소형 대장균(etec) 고스트 백신 조성물
KR20200098615A (ko) 2017-12-12 2020-08-20 콘트라펙트 코포레이션 사람 혈청의 존재하에 슈도모나스 아에루기노사에 대해 살균 활성을 갖는 리신 및 이의 유도체
US10988520B2 (en) 2018-03-29 2021-04-27 Contrafect Corporation Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
MX2020010075A (es) 2018-03-29 2021-01-08 Contrafect Corp Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos.
WO2019191598A1 (en) 2018-03-29 2019-10-03 Contrafect Corporation Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria
MX2020010076A (es) * 2018-08-23 2021-01-08 Contrafect Corp Construcciones de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos.
US20210324359A1 (en) * 2020-04-17 2021-10-21 Contrafect Corporation Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in treating endocarditis

Also Published As

Publication number Publication date
EP3775192A2 (en) 2021-02-17
EP3775192A4 (en) 2022-06-01
RU2020129467A (ru) 2022-05-04
JP2021519083A (ja) 2021-08-10
IL277119A (en) 2020-10-29
AU2019245369A1 (en) 2020-10-29
WO2019191633A2 (en) 2019-10-03
WO2019191633A3 (en) 2019-11-07
CN112368376A (zh) 2021-02-12
US20240018192A1 (en) 2024-01-18
KR20200136980A (ko) 2020-12-08
CA3095484A1 (en) 2019-10-03
US11773140B2 (en) 2023-10-03
BR112020019484A2 (pt) 2021-01-12
US20210047374A1 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
MX2020010075A (es) Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos.
EA202190906A1 (ru) Рекомбинантное получение препаратов пептидов коллагена и их применение
ZA202306237B (en) Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
MX2024002398A (es) Proteinas de fusion gdf15 y usos de estas.
MX2017004488A (es) Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso.
EA201891589A1 (ru) Условно активные гетеродимерные полипептиды и способы их применения
SA518390954B1 (ar) لقاحات علاجية لفيروس الورم الحليمي البشري 18
EA201792651A1 (ru) Аденовирусные полинуклеотиды и полипептиды
TW201613958A (en) MIC-1 fusion proteins and uses thereof
IL277120A (en) Antimicrobial Peptide Lysine Polypeptide Templates, Lysines, Isolated Polynucleotides Encoding Them and Their Uses
ZA202208710B (en) Anti-vegf protein compositions and methods for producing the same
MX2021003475A (es) Metodos de purificacion de proteinas.
AU2015269210A8 (en) Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
PH12020551019A1 (en) IL-22 Fc FUSION PROTEINS AND METHODS OF USE
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
AU2021214163A1 (en) Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
MX2021000263A (es) Proteina de fusion variante sirpalfa-4-1bbl y procedimientos de uso de la misma.
MX2021001129A (es) Metodo de purificacion de antigenos.
MX2020007628A (es) Composiciones y metodos de uso.
EA201792362A8 (ru) Композиции и способы для лечения целиакии спру
PE20161406A1 (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas
CO2020016105A2 (es) Proteínas inmunodominantes y fragmentos en esclerosis múltiple
MX2021014856A (es) Vacuna de tgf-beta.
MX2018000023A (es) Particulas semejantes a virus recombinantes que utilizan la proteina gag del virus de inmunodeficiencia bovina.
EP4058468A4 (en) POLYPEPTIDE CONSTRUCTIONS OF ANTIMICROBIAL PEPTIDE LYSINE (AMP), LYSINES, ISOLATED POLYNUCLEOTIDES ENCODING THEREFOR AND USES THEREOF